Turbine, a biotech company specializing in AI-driven cell simulations, has announced a research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to simulate cancer patient populations that are difficult to study in laboratory settings. Using Turbine’s proprietary Simulated Cells™, the partnership aims to uncover novel dependencies in highly resistant tumor types, guiding MSD’s experimental efforts to validate novel drug targets, biomarkers and rational combination therapies. The initial one-year agreement includes an option for MSD to extend access to Turbine’s virtual lab and tumor models.
